As Pradaxa Lawsuits Mount, Bernstein Liebhard LLP Notes Acknowledgement That Serious Bleeding Events Were Omitted From Important Pradaxa Clinical Trial Report

New York, New York (PRWEB) May 28, 2014

As Pradaxa lawsuits ( continue to mount in federal court, Bernstein Liebhard LLP notes that the manufacturer of the blood thinner has acknowledged that a number of serious bleeding events were omitted from the original report on a clinical trial that played a major role in garnering regulatory approval for the drug. According to a press release issued by Boehringer Ingelheim GmbH on May 14th, some 22 such events were omitted from the original report on the RE-LY trial, including five that occurred among patients taking the 150 mg dose of Pradaxa, 11 among those treated with a 110 mg dose, and six among patients who were using warfarin. Despite these findings, however, Boehringer Ingelheim maintains that the additional events do not change RE-LYs conclusions that Pradaxa is a safe and effective medication.

Our Firm is evaluating Pradaxa bleeding claims on behalf of individuals who allegedly suffered life-threatening internal hemorrhaging due to this medication. These revelations are of great interest, says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free and confidential case evaluations to patients who were allegedly harmed by Pradaxa.

Pradaxa Bleeding Allegations

Pradaxa is a blood-thinning drug approved to prevent strokes in people with atrial fibrillation. According to a report from, the RE-LY trial involved some 18,000 patients. Boehringer Ingelheim launched a review of its findings earlier this year, after attorneys representing plaintiffs in Pradaxa lawsuits uncovered a number of serious bleeding events and deaths that had been omitted from the original report.*

According to court documents, more than 2,400 claims have been filed in the U.S. District Court, Southern District of Illinois on behalf of plaintiffs who allege that Boehringer Ingelheim failed to provide adequate warnings about the drugs risks, particularly the fact that there exists no readily-available reversal agent for Pradaxas bleeding side effects. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation MDL No. 2385)

In February, 7 Action News in Detroit revealed that among all of the drugs monitored by the U.S. Food & Drug Administration (FDA), Pradaxa was the subject of the most complaints in both 2010 and 2011. The broadcast also noted that the FDA has received reports of 12,494 injuries and 1,158 deaths among Pradaxa users since the blood thinner was launched in the U.S. in October 2010. Many of these cases detailed episodes of uncontrollable internal bleeding among Pradaxa patients.**

Alleged victims of Pradaxa bleeding side effects may be entitled to compensation for their injury-related damages. To learn more about filing a Pradaxa lawsuit, please visit Bernstein Liebhard LLPs website, or call 800-511-5092 to schedule a free, no obligation case review.

*, Boehringer Ingelheim, May 14, 2014

**,, May 14, 2014

**, 7 Action News, February 25, 2014

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $ 3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York States contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firms fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiffs recovery.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016



Leave a Reply